WO2018153508A3 - Inhibiteurs de la sulfoximine glycosidase - Google Patents

Inhibiteurs de la sulfoximine glycosidase Download PDF

Info

Publication number
WO2018153508A3
WO2018153508A3 PCT/EP2017/071385 EP2017071385W WO2018153508A3 WO 2018153508 A3 WO2018153508 A3 WO 2018153508A3 EP 2017071385 W EP2017071385 W EP 2017071385W WO 2018153508 A3 WO2018153508 A3 WO 2018153508A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfoximine
glycosidase inhibitors
glycosidase
inhibitors
tauopathies
Prior art date
Application number
PCT/EP2017/071385
Other languages
English (en)
Other versions
WO2018153508A2 (fr
Inventor
Anna Quattropani
Santosh S. Kulkarni
Awadut Gajendra Giri
Original Assignee
Asceneuron S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/054280 external-priority patent/WO2017144639A1/fr
Priority claimed from PCT/EP2017/054268 external-priority patent/WO2017144633A1/fr
Priority to EA201991697A priority Critical patent/EA201991697A1/ru
Priority to EP17758140.2A priority patent/EP3585783A2/fr
Priority to KR1020197027278A priority patent/KR20190118184A/ko
Priority to JP2019545961A priority patent/JP7082446B2/ja
Priority to CA3053200A priority patent/CA3053200C/fr
Priority to BR112019017514-8A priority patent/BR112019017514A2/pt
Priority to AU2017400271A priority patent/AU2017400271B2/en
Priority to CN201780089984.7A priority patent/CN110770226B/zh
Application filed by Asceneuron S.A. filed Critical Asceneuron S.A.
Priority to US16/488,139 priority patent/US11261183B2/en
Priority to PCT/EP2017/071385 priority patent/WO2018153508A2/fr
Priority to KR1020237005097A priority patent/KR102620279B1/ko
Priority to MX2019010085A priority patent/MX2019010085A/es
Priority to SG11201907774VA priority patent/SG11201907774VA/en
Publication of WO2018153508A2 publication Critical patent/WO2018153508A2/fr
Publication of WO2018153508A3 publication Critical patent/WO2018153508A3/fr
Priority to IL268501A priority patent/IL268501A/en
Priority to ZA2019/05405A priority patent/ZA201905405B/en
Priority to US17/552,100 priority patent/US20220177470A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) dans laquelle A, R, W, Q, n et m ont la signification indiquée dans les revendications, ces composés pouvant être utilisés, entre autres, pour le traitement de tauopathies et de la maladie d'Alzheimer.
PCT/EP2017/071385 2016-02-25 2017-08-24 Inhibiteurs de la sulfoximine glycosidase WO2018153508A2 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
MX2019010085A MX2019010085A (es) 2017-02-24 2017-08-24 Inhibidores de la glicosidasa de sulfoximina.
SG11201907774VA SG11201907774VA (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors
US16/488,139 US11261183B2 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
KR1020197027278A KR20190118184A (ko) 2016-02-25 2017-08-24 술폭시민 글리코시다제 억제제
JP2019545961A JP7082446B2 (ja) 2016-02-25 2017-08-24 スルホキシイミングリコシダーゼ阻害剤
CA3053200A CA3053200C (fr) 2016-02-25 2017-08-24 Inhibiteurs de la sulfoximine glycosidase
BR112019017514-8A BR112019017514A2 (pt) 2016-02-25 2017-08-24 Composto, mistura, métodos para tratar uma tauopatias e para inibir uma glicosidase, e, composição farmacêutica
AU2017400271A AU2017400271B2 (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors
CN201780089984.7A CN110770226B (zh) 2016-02-25 2017-08-24 亚砜亚胺糖苷酶抑制剂
EA201991697A EA201991697A1 (ru) 2016-02-25 2017-08-24 Сульфоксиминовые ингибиторы гликозидазы
EP17758140.2A EP3585783A2 (fr) 2016-02-25 2017-08-24 Inhibiteurs de la sulfoximine glycosidase
PCT/EP2017/071385 WO2018153508A2 (fr) 2017-02-24 2017-08-24 Inhibiteurs de la sulfoximine glycosidase
KR1020237005097A KR102620279B1 (ko) 2016-02-25 2017-08-24 술폭시민 글리코시다제 억제제
IL268501A IL268501A (en) 2016-02-25 2019-08-05 Sulfoxyamine glycosidase inhibitors
ZA2019/05405A ZA201905405B (en) 2016-02-25 2019-08-15 Sulfoximine glycosidase inhibitors
US17/552,100 US20220177470A1 (en) 2016-02-25 2021-12-15 Sulfoximine glycosidase inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2017/054280 WO2017144639A1 (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases
PCT/EP2017/054268 WO2017144633A1 (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases
EPPCT/EP2017/054280 2017-02-24
EPPCT/EP2017/054268 2017-02-24
PCT/EP2017/071385 WO2018153508A2 (fr) 2017-02-24 2017-08-24 Inhibiteurs de la sulfoximine glycosidase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/054268 Continuation-In-Part WO2017144633A1 (fr) 2016-02-25 2017-02-24 Inhibiteurs de glycosidases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/488,139 A-371-Of-International US11261183B2 (en) 2016-02-25 2017-08-24 Sulfoximine glycosidase inhibitors
US17/552,100 Division US20220177470A1 (en) 2016-02-25 2021-12-15 Sulfoximine glycosidase inhibitors

Publications (2)

Publication Number Publication Date
WO2018153508A2 WO2018153508A2 (fr) 2018-08-30
WO2018153508A3 true WO2018153508A3 (fr) 2019-02-21

Family

ID=59686981

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2017/071385 WO2018153508A2 (fr) 2016-02-25 2017-08-24 Inhibiteurs de la sulfoximine glycosidase
PCT/EP2017/071384 WO2018153507A1 (fr) 2016-02-25 2017-08-24 Inhibiteurs de dihydrobenzofurane glycosidase substitués

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/071384 WO2018153507A1 (fr) 2016-02-25 2017-08-24 Inhibiteurs de dihydrobenzofurane glycosidase substitués

Country Status (5)

Country Link
EP (2) EP3585779A1 (fr)
AU (1) AU2017400271B2 (fr)
MX (1) MX2019010085A (fr)
SG (1) SG11201907774VA (fr)
WO (2) WO2018153508A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40532A (fr) 2014-08-28 2021-04-28 Asceneuron Sa Inhibiteurs de glycosidases
WO2017144639A1 (fr) 2016-02-25 2017-08-31 Asceneuron S. A. Inhibiteurs de glycosidases
EA201891438A1 (ru) 2016-02-25 2019-01-31 Асенейрон С. А. Кислотно-аддитивные соли производных пиперазина
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039029A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Composés spiro utilisés en tant qu'inhibiteurs de glycosidases
EA202190275A1 (ru) * 2018-08-22 2021-08-02 Асенейрон С. А. Сукцинатные и фумаратные кислотно-аддитивные соли производных пиперазина, пригодные в качестве ингибиторов гликозидазы
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094799A2 (fr) * 2001-05-22 2002-11-28 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de 1-benzyl-4-aryl piperazine substituee
WO2014159234A1 (fr) * 2013-03-14 2014-10-02 Merck Patent Gmbh Inhibiteurs de glycosidases
WO2016030443A1 (fr) * 2014-08-28 2016-03-03 Asceneuron Sa Inhibiteurs de glycosidases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (fr) 1963-11-19
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
WO1999021850A1 (fr) 1997-10-24 1999-05-06 Neurogen Corporation Piperazines de 1-(2-naphtyle) et de 1-(2-azanaphtyle)-4-(1-phenylmethyle)en tant que ligands pour le sous-type du recepteur de la dopamine d¿4?
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
US8334310B2 (en) 2006-08-31 2012-12-18 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2215075B1 (fr) 2007-10-26 2013-12-11 Janssen Pharmaceutica, N.V. Dérivés de quinolinone en tant qu'inhibiteurs parp
WO2014032187A1 (fr) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Inhibiteurs de glycosidases et leurs utilisations
EA201891438A1 (ru) * 2016-02-25 2019-01-31 Асенейрон С. А. Кислотно-аддитивные соли производных пиперазина
CN108884077A (zh) * 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
WO2017144639A1 (fr) * 2016-02-25 2017-08-31 Asceneuron S. A. Inhibiteurs de glycosidases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094799A2 (fr) * 2001-05-22 2002-11-28 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de 1-benzyl-4-aryl piperazine substituee
WO2014159234A1 (fr) * 2013-03-14 2014-10-02 Merck Patent Gmbh Inhibiteurs de glycosidases
WO2016030443A1 (fr) * 2014-08-28 2016-03-03 Asceneuron Sa Inhibiteurs de glycosidases

Also Published As

Publication number Publication date
EP3585779A1 (fr) 2020-01-01
MX2019010085A (es) 2019-11-21
AU2017400271A1 (en) 2019-08-22
SG11201907774VA (en) 2019-09-27
AU2017400271B2 (en) 2020-09-24
WO2018153508A2 (fr) 2018-08-30
WO2018153507A1 (fr) 2018-08-30
EP3585783A2 (fr) 2020-01-01

Similar Documents

Publication Publication Date Title
MX2018010192A (es) Inhibidores de glucosidasa.
MX2018010191A (es) Inhibidores de glucosidasa.
WO2018153508A3 (fr) Inhibiteurs de la sulfoximine glycosidase
ZA201701299B (en) Glycosidase inhibitors
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SG11201901061QA (en) Heterocyclic compound
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
PH12018500061A1 (en) Oxysterols and methods of use thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
NZ746825A (en) Oxysterols and methods of use thereof
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
EP4316591A3 (fr) Oxystérols et leurs procédés d'utilisation
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2021015514A (es) Compuesto heterociclico.
WO2018194181A8 (fr) Composés hétérocycliques utiles en tant que modulateurs des récepteurs de l'acétylcholine
MX2019006768A (es) Peptidos antimicrobianos.
MY193239A (en) Novel b-lactamase inhibitors
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17758140

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3053200

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017400271

Country of ref document: AU

Date of ref document: 20170824

Kind code of ref document: A

Ref document number: 2019545961

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019017514

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197027278

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017758140

Country of ref document: EP

Effective date: 20190924

ENP Entry into the national phase

Ref document number: 112019017514

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190822